Evidence map›Paper›PMID 33319198›Full record

ArticleKidney medicine

Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan.

Eiichiro Kanda, Naoki Kashihara, Shun Kohsaka, Suguru Okami, Toshitaka Yajima

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. [Acute disorders of potassium homeostasis : Diagnosis and emergency treatment].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Observational
  12. Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Eiichiro KandaMedical Science, Kawasaki Medical School, Okayama, Japan.
Naoki KashiharaDepartment of Nephrology and Hypertension, Kawasaki Medical School, Okayama, Japan.
Shun KohsakaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Suguru OkamiCardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka, Japan.
Toshitaka YajimaCardiovascular, Renal, and Metabolism, Medical Affairs, AstraZeneca K.K., Osaka, Japan.
AstraZeneca (Japan) · JPKawasaki Medical School · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveHyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia.

designObservational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). SETTING & POPULATION: : Patients 18 years or older with at least 1 serum potassium value (N = 1,208,894). EXPOSURES: Hyperkalemia defined with the presence of at least 2 serum potassium values ≥ 5.1 mmol/L. OUTCOME MEASURES: Direct health care costs and resource use in patients with hyperkalemia within and after 12 months from first hyperkalemia episodes. ANALYTICAL APPROACH: Health care costs and resource use were compared with propensity score-matched or nonmatched normokalemic controls. Multivariable regression analysis was performed to examine factors associated with health care costs.

results27,534 patients with hyperkalemia and 233,098 normokalemic controls were studied. Mean ± SD age was 73±13 years in patients with hyperkalemia; among them, 59% and 35% had chronic kidney disease and heart failure, respectively. In the propensity score-matched cohort (n = 5,859 in each group), average numbers of hospitalizations per patient per year in patients with hyperkalemia within and after 12 months were 1.2 and 1.6 times higher, respectively, compared with those in patients with normokalemia. The total cost per patient in patients with hyperkalemia was higher than for controls, with mean differences of $8,611 (95% CI, $8,046-$9,175) within 12 months and $5,150 (95% CI, $4,733-$5,566) after 12 months. The number of repeat hyperkalemic episodes was the factor with the strongest association with long-term health care costs, whereas severity of hyperkalemia was not associated. LIMITATIONS: This study used secondary data; therefore, residual confounders may not be fully excluded.

conclusionsHyperkalemia was associated with significant long-term economic burden with frequent hospitalizations due to recurrent episodes, indicating the importance of hyperkalemia treatment for the sake of reducing health economic burdens and clinical complications.

Indexed as

chronic kidney disease (CKD)healthcare costhealth economicsheart failure (HF)Hyperkalemia

Identifiers

PMID33319198
PMCPMC7729225
OpenAlexW3092709428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.